Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Description:

Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Amyloidosis Therapeutics market. – PowerPoint PPT presentation

Number of Views:352

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019


1
Amyloidosis Therapeutics - Pipeline Assessment
and Market Forecasts to 2019 Amyloidosis
Therapeutics - Pipeline Assessment and Market
Forecasts to 2019. The report is an essential
source of information and analysis on the global
Amyloidosis Therapeutics market. The report
identifies the key trends shaping and driving the
global Amyloidosis Therapeutics market. To
Browse This Report Kindly Visit
http//www.aarkstore.com/reports/Amyloidosis-Thera
peutics-Pipeline-Assessment-and-Market-Forecasts-t
o-2019-198822.html
2
Amyloidosis Therapeutics - Pipeline Assessment
and Market Forecasts to 2019 Summary Company,
the industry analysis specialist, has released
its new report, Amyloidosis Therapeutics -
Pipeline Assessment and Market Forecasts to
2019. The report is an essential source of
information and analysis on the global
Amyloidosis Therapeutics market. The report
identifies the key trends shaping and driving the
global Amyloidosis Therapeutics market. The
report also provides insights on the prevalent
competitive landscape and the emerging players
expected to significantly alter the market
positioning of the current market leaders. Most
importantly, the report provides valuable
insights on the pipeline products within the
global Amyloidosis Therapeutics sector. This
report is built using data and information
sourced from proprietary databases, primary and
secondary research and in-house analysis by
Company team of industry experts. Scope The
report provides information on the key drivers
and challenges of the Amyloidosis Therapeutics
market. Its scope includes -  - Annualized seven
key markets (US, France, Germany, Italy, Spain,
UK and Japan) Amyloidosis Therapeutics market
revenues data from 2006 to 2011, forecast for
eight years to 2019.  - Pipeline analysis data
providing a split across the different phases,
mechanisms of action being developed and emerging
trends by seven key markets. Pipeline candidates
fall under major therapeutic classes. - Analysis
of the current and future competition in the
seven key countries Amyloidosis Therapeutics
market.  - Insightful review of the key industry
drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative
analysis of its implications.  - Key topics
covered include strategic competitor assessment,
market characterization, unmet needs and the
implications for the Amyloidosis Therapeutics
market. - Analysis of key recent licensing and
partnership agreements in Amyloidosis
Therapeutics market
3
Reasons to buy The report will enhance
your decision making capability. It will allow
you to -  - Develop and design your in-licensing
and out-licensing strategies through a review of
pipeline products and technologies and by
identifying the companies with the most robust
pipeline.  - Develop business strategies by
understanding the trends shaping and driving the
global Amyloidosis Therapeutics market.  - Drive
revenues by understanding the key trends,
innovative products and technologies, market
segments and companies likely to impact the
global Amyloidosis Therapeutics market in
future.  - Formulate effective sales and
marketing strategies by understanding the
competitive landscape and by analyzing the
performance of various competitors.  - Identify
emerging players with potentially strong product
portfolios and create effective
counter-strategies to gain a competitive
advantage.  - Organize your sales and marketing
efforts by identifying the market categories and
segments that present maximum opportunities for
consolidations, investments and strategic
partnerships.  - What the next big thing in the
global Amyloidosis Therapeutics market landscape?
Identify, understand and capitalize.  
4
1.1 List of Tables 5 1.2 List of Figures 6 2
Amyloidosis Therapeutics - Introduction 7 2.1
Overview 7 2.2 Types of Amyloidosis 7 2.3
Pathophysiology of Amyloidosis 9 2.3.1
Pathophysiology of AL Amyloidosis 9 2.3.2
Pathophysiology of AA Amyloidosis 10 2.3.3
Pathophysiology of AF Amyloidosis 10 2.3.4
Pathophysiology of Aß2M Amyloidosis 10 2.3.5
Pathophysiology of Senile Amyloidosis 10 2.4
Epidemiology of Amyloidosis 11 2.4.1 Epidemiology
of AL Amyloidosis 11 2.4.2 Epidemiology of AA
Amyloidosis 11 2.4.3 Epidemiology of AF
Amyloidosis 11 2.4.4 Epidemiology of Aß2M
Amyloidosis 11 2.4.5 Epidemiology of Senile
Amyloidosis 11 2.5 Etiology of Amyloidosis 12 2.6
Risk Factors for Development of Amyloidosis
12 2.7 Signs and Symptoms of Amyloidosis 12 2.7.1
Kidney (AL, AA) 12 2.7.2 Heart (AL, AF, Senile)
12 2.7.3 Liver (AL, AA, AF) 12 2.7.4 Skin (AL,
AA) 12 2.7.5 Gastrointestinal tract (Common in
all Types) 13 2.7.6 Nervous System (Prominent in
AF) 13 2.7.7 Endocrine 13 2.7.8 Joints, Bones,
and Muscles 13 2.7.9 Respiratory System 13 2.7.10
Hematopoietic System 13 2.7.11 Other 13 2.8
Diagnosis of Amyloidosis 13 2.8.1 Physical
Examination 14 2.8.2 Biopsy 14 2.8.3 Blood Tests
14 2.8.4 Urine Tests 14 2.8.5 Imaging Techniques
14 c
5
2.9 Treatment and Management Pattern of
Amyloidosis 15 2.9.1 Treatment of AL Amyloidosis
15 2.9.2 Treatment of AA Amyloidosis 16 2.9.3
Treatment of AF Amyloidosis 16 2.9.4 Treatment of
Aß2M Amyloidosis 16 2.9.5 Treatment of Senile
Amyloidosis 16 2.10 Prognosis of Amyloidosis
17 2.11 GlobalData Pipeline Report Guidance 17 3
Amyloidosis Therapeutics - Market
Characterization 18 3.1 Amyloidosis Therapeutics
Market Size (2006-2011) - Global 18 3.2
Amyloidosis Therapeutics Market Forecast
(2011-2019) - Global 19 3.3 Amyloidosis
Therapeutics Market Size (2006-2011) - The US
20 3.4 Amyloidosis Therapeutics Market Forecast
(2011-2019) - The US 21 3.5 Amyloidosis
Therapeutics Market Size (2006-2011) - France
22 3.6 Amyloidosis Therapeutics Market Forecast
(2011-2019) - France 23 3.7 Amyloidosis
Therapeutics Market Size (2006-2011) - Germany
24 3.8 Amyloidosis Therapeutics Market Forecast
(2011-2019) - Germany 25 3.9 Amyloidosis
Therapeutics Market Size (2006-2011) - Italy
26 3.10 Amyloidosis Therapeutics Market Forecast
(2011-2019) - Italy 27 3.11 Amyloidosis
Therapeutics Market Size (2006-2011) - Spain
28 3.12 Amyloidosis Therapeutics Market Forecast
(2011-2019) - Spain 29 3.13 Amyloidosis
Therapeutics Market Size (2006-2011) - The UK
30 3.14 Amyloidosis Therapeutics Market Forecast
(2011-2019) - The UK 31 3.15 Amyloidosis
Therapeutics Market Size (2006-2011) - Japan
32 3.16 Amyloidosis Therapeutics Market Forecast
(2011-2019) - Japan 33 3.17 Drivers and Barriers
for the Amyloidosis Market 34 3.17.1 Amyloidosis
Therapeutics Market Drivers 34 3.17.2 Amyloidosis
Therapeutics Market Barriers 34 3.18 Opportunity
and Unmet Need 35
6
4 Amyloidosis Therapeutics - Competitive
Assessment 37 4.1 Overview 37 4.2 Strategic
Competitor Assessment 37 4.3 Product Profiles for
the Major Off-label Marketed Products in the
Amyloidosis Therapeutics Market 38 4.3.1
Chemotherapeutic Agents 38 4.3.2 Steroids
38 4.3.3 Immunomodulator 39 4.3.4 New Agent
39 4.4 Key Takeaway 39 5 Amyloidosis Therapeutics
- Pipeline Assessment 40 5.1 Overview 40 5.2
Strategic Pipeline Assessment 40 5.3 Amyloidosis
Therapeutics - Pipeline Assessment by Phase of
Development 40 5.3.1 Amyloidosis Therapeutics -
Recently Approved Drug 40 5.3.2 Amyloidosis
Therapeutics - Phase III Pipeline 41 5.3.3
Amyloidosis Therapeutics - Phase II Pipeline
41 5.3.4 Amyloidosis Therapeutics - Phase I
Pipeline 41 5.3.5 Amyloidosis Therapeutics -
Pre-clinical Pipeline 41 5.4 Amyloidosis
Therapeutics - Pipeline by Mechanism of Action
42 5.5 Technology Trends Analytical Framework
43 5.6 Recently Approved Drug 44 5.6.1 Vyndaqel
44 5.7 Most Promising Drugs Under Clinical
Development 45 5.7.1 Kiacta 45 5.8 Key Takeaway
47 6 Amyloidosis Therapeutics - Clinical Trials
Mapping 48 6.1 Clinical Trials by Region/Country
(US, EU5 and Japan) 48 6.2 Clinical Trials by
Phase of Clinical Development 49 6.3 Clinical
Trials by Trial Status 50 6.4 Prominent Sponsors
51 6.5 Brief Profiles of Top Companies
Participating in Therapeutic Clinical Trials 53 7
Amyloidosis Therapeutics - Strategic Assessment
54 7.1 Key Events Impacting the Future Market
54 7.2 Future Market Competition Scenario 55 8
Amyloidosis Therapeutics - Future Players 56
7
8.1 Introduction 56 8.2 Company Profiles 57 8.2.1
Pfizer Inc. 57 8.2.2 Bellus Health Inc. 59 9
Amyloidosis Therapeutics - Licensing and
Partnership Deals 61 10 Amyloidosis Therapeutics
- Appendix 62 10.1 Market Definitions 62 10.2
Acronyms 62 10.3 Research Methodology 63 10.3.1
Coverage 63 10.3.2 Secondary Research 63 10.3.3
Forecasting 64 10.3.4 Primary Research 66 10.3.5
Expert Panel Validation 67 10.4 Contact Us
67 10.5 Disclaimer 67 10.6 Bibliography 68 
8
1.1 List of Tables Table 1 Amyloid Fibril
Protein and Precursor 8 Table 2 Major Organs
Involved in Most Common Types of Amyloidosis
8 Table 3 Amyloidosis Therapeutics Market,
Global, Revenue (bn), 2006-2011 18 Table 4
Amyloidosis Therapeutics, Market, Global,
Forecast (bn), 2011-2019 19 Table 5 Amyloidosis
Therapeutics Market, The US, Revenue (bn),
2006-2011 20 Table 6 Amyloidosis Therapeutics
Market, The US, Forecasts (bn), 2011-2019
21 Table 7 Amyloidosis Therapeutics Market,
France, Revenue (m), 2006-2011 22 Table 8
Amyloidosis Therapeutics Market, France,
Forecasts (m), 2011-2019 23 Table 9 Amyloidosis
Therapeutics Market, Germany, Revenue (m),
2006-2011 24 Table 10 Amyloidosis Therapeutics
Market, Germany, Forecasts (m), 2011-2019
25 Table 11 Amyloidosis Therapeutics Market,
Italy, Revenue (m), 2006-2011 26 Table 12
Amyloidosis Therapeutics Market, Italy, Forecasts
(m), 2011-2019 27 Table 13 Amyloidosis
Therapeutics Market, Spain, Revenue (m),
2006-2011 28 Table 14 Amyloidosis Therapeutics
Market, Spain, Forecasts (m), 2011-2019 29 Table
15 Amyloidosis Therapeutics Market, The UK,
Revenue (m), 2006-2011 30 Table 16 Amyloidosis
Therapeutics Market, The UK, Forecasts (m),
2011-2019 31 Table 17 Amyloidosis Therapeutics
Market, Japan, Revenue (m), 2006-2011 32 Table
18 Amyloidosis Therapeutics Market, Japan,
Forecasts (m), 2011-2019 33 Table 19
Amyloidosis Therapeutics - Recently Approved Drug
40 Table 20 Amyloidosis Therapeutics - Phase III
and Approved Pipeline, 2011 41 Table 21
Amyloidosis Therapeutics - Phase II Pipeline,
2011 41 Table 22 Amyloidosis Therapeutics -
Phase I Pipeline, 2011 41 Table 23 Amyloidosis
Therapeutics - Pre-clinical Pipeline, 2011
41 Table 24 Amyloidosis Therapeutics Market -
Most Promising Drugs Under Clinical Development,
2011 45 Table 25 Amyloidosis Therapeutics -
Clinical Trials by Country, 2011 48 Table 26
Amyloidosis Therapeutics, Major Markets -
Clinical Trials by Phase, 2011 49 Table 27
Amyloidosis Therapeutics, Major Markets, Clinical
Trials by Development Status, 2011 50 Table 28
Amyloidosis Therapeutics, Major Markets,
Prominent Sponsors, 2011 52 Table 29 Amyloidosis
Therapeutics, Major Markets, Clinical Trials of
Top Companies by Phase, 2011 53 Table 30 Pfizer
Inc. - Amyloidosis Pipeline, 2011 59 Table 31
Bellus Health - Amyloidosis Pipeline, 2011
59 Table 32 Amyloidosis Therapeutics Market -
Future Players 60 
9
1.2 List of Figures Figure 1 Amyloidosis on
Face 11 Figure 2 Amyloidosis Therapeutics
Market, Global, Revenue (bn), 2006-2011
18 Figure 3 Amyloidosis Therapeutics Market,
Global, Forecast (bn), 2011-2019 19 Figure 4
Amyloidosis Therapeutics Market, The US, Revenue
(bn), 2006-2011 20 Figure 5 Amyloidosis
Therapeutics Market, The US, Forecast (bn),
2011-2019 21 Figure 6 Amyloidosis Therapeutics
Market, France, Revenue (m), 2006-2011 22 Figure
7 Amyloidosis Therapeutics Market, France,
Forecast (m), 2011-2019 23 Figure 8 Amyloidosis
Therapeutics Market, Germany, Revenue (m),
2006-2011 24 Figure 9 Amyloidosis Therapeutics
Market, Germany, Forecast (m), 2011-2019
25 Figure 10 Amyloidosis Therapeutics Market,
Italy, Revenue (m), 2006-2011 26 Figure 11
Amyloidosis Therapeutics Market, Italy, Forecast
(m), 2011-2019 27 Figure 12 Amyloidosis
Therapeutics Market, Spain, Revenue (m),
2006-2011 28 Figure 13 Amyloidosis Therapeutics
Market, Spain, Forecast (m), 2011-2019 29 Figure
14 Amyloidosis Therapeutics Market, The UK,
Revenue (m), 2006-2011 30 Figure 15 Amyloidosis
Therapeutics Market, The UK, Forecast (m),
2011-2019 31 Figure 16 Amyloidosis Therapeutics
Market, Japan, Revenue (m), 2006-2011 32 Figure
17 Amyloidosis Therapeutics Market, Japan,
Forecast (m), 2011-2019 33 Figure 18
Opportunity and Unmet Need in the Amyloidosis
Therapeutics Market, 2011 35 Figure 19 Strategic
Competitor Assessment, 2011 37 Figure 20
Amyloidosis Therapeutics Market - Pipeline by
Phase of Development, 2011 40 Figure 21
Amyloidosis Therapeutics - Clinical Pipeline by
Mechanism of Action, 2011 42 Figure 22
Technology Trends Analytics Framework, 2011
43 Figure 23 Technology Trends Analytics
Framework - Description, 2011 44 Figure 24
Amyloidosis Therapeutics - Clinical Trials by
Country, 2011 48 Figure 25 Amyloidosis
Therapeutics, Major Markets - Clinical Trials by
Phase, 2011 49 Figure 26 Amyloidosis
Therapeutics, Major Markets, Clinical Trials by
Development Status, 2011 50 Figure 27
Amyloidosis Therapeutics, Major Markets, Overall
Sponsors, 2011 51 Figure 28 Amyloidosis
Therapeutics, Major Markets, Prominent Sponsors,
2011 52 Figure 29 Amyloidosis Therapeutics,
Major Markets, Clinical Trials of Top Companies
by Phase, 2011 53 Figure 30 Amyloidosis
Therapeutics Market, Drivers and Restraints 2011
54 Figure 31 Implications for Future Market
Competition in the Amyloidosis Therapeutics
Market, 2011 55 Figure 32 Amyloidosis
Therapeutics Market - Pipeline by Company, 2011
56 Figure 33 GlobalData Market Forecasting Model
66  Company Mentioned Pfizer Inc. Bellus Health
Inc.
10
Related Reports
  • For more information, please visit
  • http//www.aarkstore.com/reports/Amyloidosis-Thera
    peutics-Pipeline-Assessment-and-Market-Forecasts-t
    o-2019-198822.html
  • Or email us at contact_at_aarkstore.com or call
    919272852585
  • More Reports
  • http//www.aarkstore.com/publishers/GlobalData-61.
    html
  • Bioinformatics Partnering Terms and Agreements
  • 2013 Deep Research Report on Global and China
    Human Coagulation Factor ? Industry
  • Competing in the European Clinical Chemistry and
    Immunodiagnostic Markets France, Germany, Italy,
    Spain, UK
  • Competing in the European Coagulation Testing
    Market France, Germany, Italy, Spain, UK
  • Competing in the European Blood Banking
    Market France, Germany, Italy, Spain, UK
  • HIV / AIDS Pipeline Review, H1 2013
  • Parkinsons Disease Pipeline Review, H1 2013
  • Autoimmune Disorders Pipeline Review, H1 2013
  • Colon Cancer Pipeline Review, H1 2013
  • Metastatic Colorectal Cancer Pipeline Review,
    H1 2013

11
Contact Us Aarkstore Enterprise Tel
912227453309 Mobile No08149852585 Email
contact_at_aarkstore.com Website
http//www.aarkstore.com Blog http//www.emarketr
eports.com http//teju-aarkstoreenterprise.blogspo
t.in Follow us on twitter http//twitter.com/aark
storedotcom http//in.linkedin.com/in/aarkstore ht
tp//www.facebook.com/aarkstoreenterprise
About PowerShow.com